20 November 2020 - - US-based breast cancer precision oncology company Agendia, Inc and AI-based digital diagnostics company Paige have forged strategic partnership, the companies said.

The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia's proprietary MammaPrint and BluePrint diagnostic tests for patients with breast cancer.

These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.

The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead.

This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.

Agendia is a precision oncology company headquartered in Irvine, California. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions.